Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
15 The decrease in enzymes related to NAD + de novo synthesis is due to the inhibition of the activity of PPAR coactivator 1 (PGC-1), which is a crucial determinant of renal recovery from AKI
Wiedemann et al., 1999)
Weeks 1-4: 1mg weekly (4mg total, small portion of first vial) Weeks 5-8: 2mg weekly (8mg total) Weeks 9-12: 4mg weekly (16mg total, finish first vial and start second) Weeks 13-16: 6mg weekly (24mg total, continue through second vial) Weeks 17-20: 8mg weekly (32mg total) Weeks 21-24: 8mg weekly maintenance (32mg total) Total peptide required: 116mg over 24 weeks Vials needed: 6 x 20mg vials with some remaining This protocol reaches 8mg maintenance by week 17 and holds there through week 24
In the response comments in the final ASC rule, CMS states: we have concerns about these services being furnished in non-facility settings
The compound's interaction with multiple pathways (hormonal, vascular, and neural) introduces unresolved concerns about long-term effects
More research in humans is needed
